



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road
No.6, Sy.No.33, 34P to 39, Guttala Begumpet,
Jubilee Hills, Hyderabad, Shaikpet, Telangana,
India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

April 22, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: VIYASH

Subject: Outcome of Board Meeting

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), we hereby inform you that the Board of Directors of the Company, at its meeting held today:

(a) Approved the appointment of Mr. Amit Jain (DIN: 06917608) as an Additional Director (Non-Executive, Non-Independent) of the Company.

Based on the recommendation of the Nomination and Remuneration Committee (“**NRC**”), the Board has approved the appointment of Mr. Amit Jain, (DIN: 06917608), representing Carlyle group, as an Additional Director of the Company with effect from April 22, 2026, to hold office as a Non-Executive, Non- Independent Director of the Company, liable to retire by rotation, subject to the approval of the shareholders.

(b) Approved the appointment of Mr. Abhiroop Jayanthi (DIN: 10354445) as an Additional Director (Non- Executive, Non-Independent) of the Company.

Based on the recommendation of the NRC, the Board has approved the appointment of Mr. Abhiroop Jayanthi, (DIN: 10354445), representing Carlyle group, as an Additional Director of the Company with effect from April 22, 2026, to hold office as a Non-Executive, Non- Independent Director of the Company, liable to retire by rotation, subject to the approval of the shareholders.

The details under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure A & B**.



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road
No.6, Sy.No.33, 34P to 39, Guttala Begumpet,
Jubilee Hills, Hyderabad, Shaikpet, Telangana,
India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

(c) Approved revised ESOP Pool Viyash Scientific Limited Employee Stock Option Scheme 2026 ("ESOP 2026")

The total number of stock options proposed to be granted under ESOP 2026 was 1,34,75,000 stock options. Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved a revised option pool of 1,30,98,000 stock options under ESOP 2026. All other details, as required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, have already been disclosed in the Company's intimation dated February 05, 2026.

The Board Meeting commenced at 11:30 a.m. and concluded at 12:39 p.m.

Yours faithfully,
For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

Yoshita Vora
Company Secretary & Compliance Officer
Encl: A/a



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)
 Registered Office:
 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033
 T: +91 40 23635000,
 E: investorrelations@viyash.com
 Website: www.viyash.com
 CIN: L99999TS1985PLC196357

Annexure A

Mr. Amit Jain [DIN: 06917608]		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Amit Jain (DIN: 06917608) as an Additional Director designated as Non-executive, Non-Independent Director of the Company with effect from April 22, 2026
b.	Date of Appointment/ reappointment/cessation (as applicable) and term of appointment/ reappointment	With effect from April 22, 2026, as recommended by Nomination and Remuneration Committee and approved by the Board, liable to retire by rotation, subject to approval of shareholders.
c.	Brief Profile (in case of appointment)	<p>Mr. Amit Jain is a Partner and Head of Carlyle India Advisors, where he oversees Carlyle's India operations and private equity team, and leads local investment and portfolio company activities across the technology, consumer, advanced manufacturing and industrial sectors. Mr. Jain has both deep private equity and industry experience and specializes in buyout and control investments. He is based in Mumbai and is a core member of the senior leadership team for Carlyle in Asia.</p> <p>Mr. Jain joined Carlyle in 2021 after 10 years at Blackstone in India where he last served as Senior Managing Director in its Private Equity Group and focused on investments across the consumer, healthcare, automotive, telecommunications and financial services industries. Prior to that, Mr. Jain was a consultant at McKinsey & Company and started his career with Unilever in India in operating roles.</p> <p>He currently serves on the boards of several Carlyle portfolio companies, including Quest Global, Piramal Healthcare, VLCC, Highway Roop, Varmora Granito, and Strata Geosystems, Knack Global & Aastra. He has also previously held board positions at EPL, Aakash Educational Services, SONA BLW Precision Forgings and FINO Payments Banks, amongst others.</p> <p>Mr. Jain is currently a member of the Executive Committee of the Indian Private Equity and Venture Capital Association (IVCA) and was recognized by The Economic Times as one of India's "40 Under 40" young business leaders in 2019. He holds an MBA from the Indian School of Business, Hyderabad and a Bachelor of Technology in Mechanical Engineering from the Indian Institute of Technology (IIT), Kharagpur</p>



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000,

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

d.	Disclosure of relationships between directors (in case of appointment of a director)	NA
e.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Based on the declaration received from Mr. Amit Jain, he is not debarred from holding the office of director pursuant to any SEBI order or any other authority.



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)
 Registered Office:
 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033
 T: +91 40 23635000,
 E: investorrelations@viyash.com
 Website: www.viyash.com
 CIN: L99999TS1985PLC196357

Annexure B

Mr. Abhiroop Jayanthi [DIN: 10354445]		
Sr. No.	Particulars	Details
a.	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Abhiroop Jayanthi (DIN: 10354445) as an Additional Director designated as Non-executive, Non-Independent Director of the Company with effect from April 22, 2026
b.	Date of Appointment/ reappointment/cessation (as applicable) and term of appointment/ reappointment	With effect from April 22, 2026, as recommended by Nomination and Remuneration Committee and approved by the Board, liable to retire by rotation, subject to approval of shareholders.
c.	Brief Profile (in case of appointment)	<p>Mr. Abhiroop Jayanthi is a Managing Director and member of the Asia Private Equity team at Carlyle, the leading global investment firm with USD 465 billion of assets under management. In his role he advises on investments in India with a focus on healthcare and life sciences, advanced manufacturing, and industrial sectors.</p> <p>With 15 years of experience in private equity, Mr. Jayanthi has been involved in multiple investments across a diverse range of industries. Prior to joining Carlyle, he was a Managing Director at Bain Capital, where he led investments across healthcare, life sciences, technology, and industrials sectors. In recognition of his leadership and contributions to the business landscape, Mr. Abhiroop was named one of India's most promising young corporate leaders by The Economic Times in 2014.</p> <p>Mr. Jayanthi holds an MBA from the Wharton Business School, where he was a Palmer Scholar. He earned his undergraduate degree in Industrial Engineering from the Indian Institute of Technology (IIT) Delhi, where he was awarded the Director's Gold Medal for Outstanding All-Round Achievement and Leadership. He also holds a Postgraduate Diploma in Finance and Financial Law from the University of London.</p>
d.	Disclosure of relationships between directors (in case of appointment of a director)	NA
e.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Based on the declaration received from Mr. Abhiroop Jayanthi, he is not debarred from holding the office of director pursuant to any SEBI order or any other authority.